title: Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors.
abstract: BACKGROUND
  It is still not known whether hematopoiesis reconstituted by autografting with the peripheral blood hematopoietic progenitors (CPCs) after myeloablative high dose radiotherapy and/or chemotherapy is durable and capable of coping with the increased demand imposed by boost radiotherapy, surgery, or infection.
  
  
  METHODS
  The durability of hematopoiesis was evaluated in 34 consecutive cancer patients treated with myeloablative total body irradiation (n = 17, median follow-up 3 years, range 3-49 months) and/or alkylating-agent chemotherapy (n = 17, median follow-up 8 months, range 6-41 months) and autografted with CPCs because bone marrow autografting was contraindicated. CPCs (> or = 8 x 10(6) CD34 + cells/kg) had been collected during mobilization into the circulation in response to previous anticancer therapy and hematopoietic growth factor(s).
  
  
  RESULTS
  Following brief temporary pancytopenia, all patients achieved normal and durable hematopoiesis. The newly reconstituted hematopoietic system was capable of reacting favorably to stressful and debilitating events such as surgery, radiotherapy, or varicella-zoster infection. No secondary irreversible failure of blood cell production occurred.
  
  
  CONCLUSIONS
  The documentation of the durability of normal hematopoiesis following myeloablative cancer therapy and autografting with mobilized CPCs implies that the latter procedure, rather than being solely an alternative to bone marrow autografting, represents an advantageous tool of choice permitting substantial amelioration of the therapeutic index of high-dose cancer therapy.
authors.affiliation: Cristina Gandini Transplantation Unit, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Siena
authors.forename: M
authors.initials: M
authors.lastname: Bregni
authors.forename: M
authors.initials: M
authors.lastname: Di Nicola
authors.forename: F
authors.initials: F
authors.lastname: Ravagani
authors.forename: F
authors.initials: F
authors.lastname: Peccatori
authors.forename: L
authors.initials: L
authors.lastname: Gandola
authors.forename: F
authors.initials: F
authors.lastname: Lombardi
authors.forename: C
authors.initials: C
authors.lastname: Tarella
authors.forename: G
authors.initials: G
authors.lastname: Bonadonna
authors.forename: A M
authors.initials: AM
authors.lastname: Gianni
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006410:Hematopoiesis; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy; D013997:Time Factors; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
chemical_list: D016298:Hematopoietic Cell Growth Factors; D003520:Cyclophosphamide